Open Access

Inhibition of the PI3K/AKT signaling pathway sensitizes diffuse large B‑cell lymphoma cells to treatment with proteasome inhibitors via suppression of BAG3

  • Authors:
    • Ting Yuan
    • Feng Zhang
    • Xiangxiang Zhou
    • Ying Li
    • Ya Zhang
    • Yangyang Xu
    • Xin Wang
  • View Affiliations

  • Published online on: February 8, 2019     https://doi.org/10.3892/ol.2019.10029
  • Pages: 3719-3726
  • Copyright: © Yuan et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: HTML 0 views | PDF 0 views     Cited By (CrossRef): 0 citations

Abstract

Proteasome inhibitors represent a novel class of drugs that have clinical efficacy against hematological and solid cancer types, including acute myeloid leukaemia, myelodysplastic syndrome an non‑small cell lung cancer. It has been demonstrated that the anti‑apoptotic protein B‑cell lymphoma‑2‑associated athanogene 3 (BAG3) is induced by proteasome inhibitors in various cancer cells and serves an important role in chemotherapy resistance. The phosphatidylinositol 3‑kinase (PI3K)/RAC‑α serine/threonine‑protein kinase (AKT) pathway is constitutively activated in a number of lymphoid malignancy types, including diffuse large B‑cell lymphoma (DLBCL) and Burkitt lymphoma. In the present study, the aim was to elucidate the role of the PI3K/AKT signaling pathway in the induction of BAG3, following exposure to a proteasome inhibitor in DLBCL cell lines. Bortezomib and MG132 were used as proteasome inhibitors. Western blotting was used to evaluate the roles of proteasome inhibitors and the PI3K/AKT pathway in BAG3 induction in DLBCL cells (LY1 and LY8), and LY294002 was used to block the PI3K/AKT pathway. Cell viability was detected using a Cell Counting Kit‑8 assay. Apoptosis of LY1 and LY8 cells was quantified by Annexin V/7‑amino‑actinomycin D flow cytometry. The BAG3 protein was markedly induced upon exposure to bortezomib and MG132 in a dose‑dependent manner. The PI3K/AKT inhibitor LY294002 significantly suppressed the induction of BAG3 by proteasome inhibitors. Inhibition of the PI3K/AKT pathway decreased the proliferation and increased the apoptosis induced by proteasome inhibitors. The present results indicated that the PI3K/AKT pathway is associated with the activation of BAG3 expression in DLBCL cells, and is involved in the protective response against proteasome inhibition.

Related Articles

Journal Cover

April 2019
Volume 17 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Yuan, T., Zhang, F., Zhou, X., Li, Y., Zhang, Y., Xu, Y., & Wang, X. (2019). Inhibition of the PI3K/AKT signaling pathway sensitizes diffuse large B‑cell lymphoma cells to treatment with proteasome inhibitors via suppression of BAG3. Oncology Letters, 17, 3719-3726. https://doi.org/10.3892/ol.2019.10029
MLA
Yuan, T., Zhang, F., Zhou, X., Li, Y., Zhang, Y., Xu, Y., Wang, X."Inhibition of the PI3K/AKT signaling pathway sensitizes diffuse large B‑cell lymphoma cells to treatment with proteasome inhibitors via suppression of BAG3". Oncology Letters 17.4 (2019): 3719-3726.
Chicago
Yuan, T., Zhang, F., Zhou, X., Li, Y., Zhang, Y., Xu, Y., Wang, X."Inhibition of the PI3K/AKT signaling pathway sensitizes diffuse large B‑cell lymphoma cells to treatment with proteasome inhibitors via suppression of BAG3". Oncology Letters 17, no. 4 (2019): 3719-3726. https://doi.org/10.3892/ol.2019.10029